In myeloid malignancies, patients with a ‘double-hit’ in a gene such as CEBPA, RUNX1, or DDX41 often have one variant in the germline with a VAF between 40 and 60%, and a second variant of somatic origin with variable VAF [52]. This evidence concerns the gene DDX41 and myeloid neoplasm.